DNA demethylating therapy reverts mesenchymal stromal cells derived from high risk myelodysplastic patients to a normal phenotype

Br J Haematol. 2017 Jun;177(5):818-822. doi: 10.1111/bjh.14115. Epub 2016 Apr 22.

Authors

Giulia Maurizi¹, Domenico Mattiucci¹, Marianna Mariani¹, Marco Ciarlantini¹, Sabrina Traini¹, Stefania Mancini¹, Attilio Olivieri¹, Pietro Leoni¹, Antonella Poloni¹

Affiliation

¹ Clinica di Ematologia, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy.

PMID: 27102230
DOI: 10.1111/bjh.14115

No abstract available

Keywords: azacitidine; demethylating agents; mesenchymal stem cell; mesenchymal stromal cell; myelodysplastic syndrome.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Azacitidine / pharmacology
Azacitidine / therapeutic use
Biomarkers
Bone Marrow / drug effects
Bone Marrow / metabolism
Bone Marrow / pathology
Cellular Microenvironment / drug effects
DNA Methylation / drug effects*
Humans
Immunophenotyping
Mesenchymal Stem Cells / drug effects*
Mesenchymal Stem Cells / metabolism*
Myelodysplastic Syndromes / drug therapy
Myelodysplastic Syndromes / genetics*
Myelodysplastic Syndromes / pathology*
Phenotype

Substances

Antineoplastic Agents
Biomarkers
Azacitidine